Background: Inflammatory breast cancer (IBC) is an aggressive disease. To date, no molecular feature reliably predicts either the response to chemotherapy (CT) or the survival. Using DNA microarrays, we searched for multigene predictors.
introduction
Inflammatory breast cancer (IBC) is rare (5% of BC) but represents the most aggressive form of disease [1] . Despite multidisciplinary treatment, 5-year overall survival is 40%. The rate of pathological complete response ( pCR) after neoadjuvant anthracycline-based chemotherapy (CT) ranges from 15% to 40%. Prognostic features are controversial. No factor reliably predicts either the response to CT or survival. Because IBC is rare and the pretreatment biopsy samples are small, past molecular studies have not been conclusive [2] . No specific molecular therapeutic target has been identified to date. A few years ago, genome-wide approaches, essentially gene expression profiling, were applied to clinical samples. Most studies showed that a molecular signature of IBC can be established [3] [4] [5] [6] [7] [8] [9] [10] , but they suffered from limitations [11] , including a nonuniform definition of IBC and small series. Two issues-prognosis and prediction of response to primary CT-were addressed only by two groups [5, 6] but in small series and without any independent validation. In contrast with non-IBC (nIBC), no robust molecular signature predictive of therapeutic response or survival has been identified for IBC.
Here, we report the results of the second project spearheaded by the World IBC Consortium, which aims at identifying molecular determinants of survival and response to CT in IBC. We generated and pooled Affymetrix expression profiles of 389 BC samples including an unprecedented number of 137 IBC samples combined with 252 nIBC samples [12] . We searched for gene expression signatures (GES) associated with pCR to neoadjuvant CT and distant metastasis-free survival (DMFS) in IBC.
materials and methods patients and samples
Tumor samples were obtained from patients treated for invasive breast adenocarcinoma at the Institut Paoli-Calmettes (IPC, Marseille), the MD Anderson Cancer Center (MDACC, Houston), or the General Hospital SintAugustinus (TCRU, Antwerp). All samples were taken before any systemic treatment: diagnostic biopsy (IBC and advanced-stage nIBC), and operative specimen (early-stage nIBC). Other selection criteria included available histoclinical annotations, notably the TNM classification, and available goodquality extracted tumor RNA. All IBC samples were from consecutively treated patients. The definition of IBC strictly adhered to the international consensus diagnostic criteria [13] : rapid onset (<6 months) of breast erythema, edema, and/or peau d'orange, and/or warm breast, with or without an underlying palpable mass. Additional information is available in the supplementary File, available at Annals of Oncology online.
IBC patients were treated with primary anthracycline-based polychemotherapy often including sequential taxane, and coupled with trastuzumab in more than 50% of cases with ERBB2 amplification. CT was followed by surgery (mastectomy and axiilary lymph node dissection) for clinically nonprogressive and consenting patients, then radiotherapy. Surgical specimens were examined to determine the pathological response to CT, which was scored on both the primary tumor and the lymph nodes using Chevallier grading [14] . Grades 1 and 2 were considered as pCR, and grades 3 and 4 as residual disease (RD). From the 137 IBC samples, 87 were available for pCR analysis (Table 1) . After radiotherapy, adjuvant hormone therapy was given to patients with ER-positive IBC, as well as adjuvant trastuzumab in cases with ERBB2 amplification. A total of 106 patients with nonmetastatic IBC were assessable for DMFS analysis, as well as 220 patients with nonmetastatic nIBC; these two groups showed histoclinical features coherent with literature (supplementary Table S2 , available at Annals of Oncology online).
expression data analysis
RNA hybridization of 389 samples on to Affymetrix GeneChips (HGU133-series) has been described [12] . More information on data processing, normalization, and analyses is available in the supplementary File, available at Annals of Oncology online. Each of the 389 samples was classified according to GES identified in nIBC patients: the molecular subtypes defined using the PAM50 predictor [15] , the nine-cell line claudin-low predictor [16] , and seven GES: five prognostic for DMFS (Recurrence Score [17] , 70-gene GES [18] , Wound-response GES [19] , Invasiveness GES [20] , and Risk of Relapse score GES based on subtype and proliferation ROR-P [15, 21] ), and two predictive for pathological response to anthracycline/taxane-based CT (stromal GES [22] and FAC/T response GES [23] ).
Supervised analysis addressed two comparisons of IBC samples: pathological response and metastatic relapse. For both analyses, we divided our dataset into learning and validation sets. P-values, corrected for multiple comparisons, were considered significant only if the false discovery rate (FDR) was smaller than 0.25, unless explicitly stated. Regarding the response analysis, our classifier was built in the learning set and its robustness was assessed in IBC by leave-one-out cross-validation in the learning set and by external validation in the independent validation set (43 samples). Then, we tested its predictive performances in a publicly available pooled set of 675 nonredundant nIBC samples defined as non-T4d and treated with neoadjuvant anthracycline-based CT followed by surgery (supplementary Table S3 , available at Annals of Oncology online). To further explore functional differences, those two supervised analyses ( pathological response, metastatic relapse) were repeated at the pathway and transcription factor levels (supplementary File, available at Annals of Oncology online, supplementary (Table 2 ). Higher pCR rate was observed in ESR1-negative samples, in GGI-high samples, in non-luminal A and non-normal-like samples, in Wound-response GES-based poor-prognosis samples and in ROR-P high-risk samples; however, differences were not significant, likely due to the series size. For example the OR for pCR was 8.6 between non-normal-like samples and luminal A samples. Significant differences were observed for three prognostic GES, with more patients with pCR in the poorprognosis groups (Recurrence Score, P = 0.029; 70-gene GES, P = 0.045; Invasiveness GES, P = 5.3E−03). The nIBC pCR-GES carried out well in IBC to predict the response: stromal GES (P = 0.010) and FAC/T response GES (P = 0.040).
We identified two immune pathways (IFNα-and INFγ-pathways) as hyperactivated in samples from patients with pCR (P = 0.015 and P = 0.001 respectively, Mann-Whitney test), as well as three pathways (EGFR, P53, TGBβ) as hypoactivated in patients with pCR (P = 0.015, P = 0.015, P = 0.004, respectively). TF analysis revealed three transcription factors (STAT5: P = 3.6E-05, GLI: P = 8.7E−04, SMAD: P = 9.6E−04, Mann-Whitney test) as hypoactivated in samples from patients with pCR after correction with FDR inferior to 20% (data not shown).
signature predictive for pCR to primary chemotherapy in IBC The 87-sample population was divided into a learning set (N = 44) and a validation set (N = 43), which displayed similar pCR rates (36% and 28%, respectively, P = 0.5, Fisher's exact test).
In the learning set, SAM (FDR inferior to 25%) identified 124 differentially expressed probe sets (107 unique genes), between responders and nonresponders, all of which were overexpressed in samples with pCR (supplementary Table S5 , available at Annals of Oncology online). Several processes related to T-celldependent immunology were strongly overrepresented in this gene list ( Figure 1A ; supplementary Table S6 , available at Annals of Oncology online), including the 'T-cell receptor signaling' canonical pathway ( Figure 1B ). We derived a predictive SVM model from the 124-probe set list in the learning set. Its validity was internally tested by LOOCV (75% of samples correctly assigned), and by external validation in the independent set of 43 samples, in which the rate of accurate classification was 81% with an odds ratio for pCR equal to 14.2 in the 'predictedpCR' subgroup compared with the 'predicted-RD' subgroup (P = 5E−04, Fisher's exact test). We further tested our model in an additional validation set including 21 pretreatment IBC samples (supplementary Table S7 , available at Annals of Oncology online): the accuracy of classification was 95% and the odds ratio for pCR was equal to infinite (P = 0.014). Combining the two validation sets (N = 64) gave a classification accuracy of 86% and an odds ratio of 24.6 (Table 3 ; P = 4.34E−06). We then compared the predictive value of our model in this combined validation set (N = 64) with that of other pretreatment variables significant in univariate analysis ( prognostic and predictive GES, IFNα, INFγ, EGFR, P53, and TGBβ activation profiles) using multivariate analysis (Table 4) . Our signature remained the strongest predictive variable with an odds ratio equal to 50.8 and showed significance despite the relatively small number of samples (P = 0.0096), suggesting additional predictive value beyond all other signatures.
We then applied the SVM modelon to gene expression data of 675 nIBC treated with neoadjuvant anthracycline-based CT. A significant correlation (P = 1.89E−03, Fisher's exact test) was observed between the predicted and observed pCR phenotypes, with an odds ratio for pCR equal to 1.94 in the 'predictedpCR' subgroup compared with the 'predicted-RD' subgroup ( Figure 1C) . Interestingly, when we incorporated into multivariate analysis the variables significant in univariate analysis (molecular subtypes, ESR1, ERBB2, GGI, and FAC/T-response GES) and our SVM model, the latter remained significant (supplementary Table S8 , available at Annals of Oncology online), suggesting an independent predictive value. Figure 2B ). By contrast, in our series of nIBC samples and after adjustment for the delivery of systemic adjuvant or neoadjuvant CT, several variables were significant in univariate analysis ( Figure 2C ; supplementary Table S9 , available at Annals of Oncology online). As expected, patients with luminal A nIBC showed better outcome than patients with basal-like or ERBB2-enriched nIBC. Finally, we searched for a GES associated with DMFS in our 106 IBC samples. In the learning set (79 samples), Cox regression analysis did not identify any significant probe set. We thus pooled the learning and validation sets and repeated the Cox analysis. The same result was observed, suggesting that no robust prognostic signature could be established. CT and the identification of predictive factors in IBC specifically. Our data suggest that similar molecular mechanisms may be involved in IBC and nIBC. First, the two prognostic nIBC-GES previously shown to be associated with pCR [24, 25] and the two predictive nIBC-GES [22, 23] effectively discriminated between IBC patients with versus without pCR. Although not significant, likely due to the relatively small series size, the ESR1 status, GGI and the molecular subtypes were associated with pathological response as described in nIBC [16] . The pCR rate was 7% for the luminal A subtype and from 30% to 45% for the other subtypes, in agreement with the nIBC literature, except for the luminal B subtype that displayed high pCR rate (30%). Second, our signature was also significantly predictive for pCR in nIBC. Third, as in nIBC [26] , the response to CT seems enhanced by a pre-existing immune response. Our signature was strongly enriched for immunity-related genes involved in CD8+ T-cell lymphocyte activation processes (Th1-response), suggesting a prominent role for adaptive immunity in determining response to CT in IBC. Innate immunity was also represented by the presence of ontologies such as 'Crosstalk between dendritic cells and natural killer cells', and 'communication between innate and adaptive immune cells'. Fourth, in multivariate analysis, both in the IBC validation set and in nIBC, our predictor showed predictive value independent from that of multigene GES, with a strong odds ratio (55.4) in IBC and significance despite the small series size. Of note, our predictor carried out well in the 22 ERBB2-positive IBC samples of the validation set independently of trastuzumab treatment (data not shown). In the future, our signature could have clinical implications. First, better predicting the pathological response to primary anthracycline-based CT could help tailoring systemic treatment: patients of the 'predicted-RD group' might be enrolled in clinical trials testing nonanthracycline-based regimens. Second, the functional validation of relevant genes, such as those involved in immunity, could lead to the development of new therapies combined or not with CT. Second, we analyzed the correlation of expression profiles with DMFS in IBC and compared with that observed in nIBC.
Although not significant likely due to the limited sample size (76 informative cases), the pathological response was the histoclinical factor displaying the largest hazard ratio (HR = 0.56; P = 0.249). We acknowledge that our analyses in IBC are underpowered because of the size limitation. Even if it seems that differences exist between IBC and nIBC regarding the metastatic phenotype and the associated transcriptional changes, no definitive conclusion may be drawn for IBC and further analysis in larger series is warranted. The difference in DMFS of subtypes in IBC and nIBC, particularly the luminal A/B subtypes, which is not due to the shorter follow-up in IBC when compared with nIBC, needs confirmation. It likely explains in part the absence of prognostic value of ESR1 expression, GGI, molecular subtypes, and tested prognostic GES in IBC when compared with nIBC. If confirmed, a speculative explanation might be the fact that, within ER-negative subtypes (i.e. basal-like and ERBB2-enriched), IBC and nIBC tumors benefit similarly from CT, whereas within the luminal A/B ER-positive subtypes, IBC tumors benefit from endocrine therapy much less than nIBC. Finally, we could not identify any robust prognostic GES in IBCs, suggesting the need for analysis of a larger series of samples to define IBC-specific prognostic signatures.
Our study presents several strengths: originality (the first multicentric study of this type in IBC, the largest series profiled so far using high-throughput molecular analyses, the first one addressing clinical issues), uniform consensual IBC definition, consistent technological platform, and identification of a response signature biologically relevant, validated in three independent sets including two IBC sets and one nIBC set, with independent significant predictive value in IBC and nIBC validation sets. The first limitation concerns the relatively small number of IBC samples, inherent to IBC research. This limitation may explain the relatively high pCR rate observed for luminal B IBC samples when compared with the public 675 nIBC series (18%). Further comparison of pCR rates in larger series of IBC and nIBC is warranted before eliminating the hypothesis that IBCs respond better to CT. The second limitation is the retrospective nature of the study. Efforts are ongoing to gather more samples inside the Word IBC Consortium.
In conclusion, our results provide novel insights into the molecular mechanisms of response to neoadjuvant CT. Response to CT in IBC, as in nIBC, is similarly associated with immunityrelated processes. Regarding DMFS, analysis of larger IBC series is warranted before concluding that different mechanisms for metastasis exist in IBC and in nIBC.
